

IONA test for first-trimester detection of trisomies 21, 18 and 13

L. C. POON, D. DUMIDRASCU-DIRIS, C. FRANCISCO, I. FANTASIA and K. H. NICOLAIDES

Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK

KEYWORDS: aneuploidy; cell-free DNA; first trimester; first-trimester screening; prenatal diagnosis

ABSTRACT

Objective To assess the potential performance of screening for fetal trisomies 21, 18 and 13 by cell-free DNA (cfDNA) analysis of maternal blood using the IONA[®] test.

Methods This was a nested case–control study of cfDNA analysis of maternal plasma using the IONA test. Samples were obtained at 11–13 weeks' gestation, before chorionic villus sampling, from 201 euploid pregnancies, 35 with trisomy 21, four with trisomy 18 and two with trisomy 13. Laboratory personnel were blinded to the fetal karyotype.

Results Probability scores for trisomies 21, 18 and 13 were given for 241/242 samples analyzed. No probability score was provided for one (0.5%) euploid pregnancy because of low fetal fraction. In all 35 cases of trisomy 21 the probability score for trisomy 21 was > 95% and the scores for trisomies 18 and 13 were ≤ 0.0001%. In all four cases of trisomy 18, the probability score for trisomy 18 was > 77% and the scores for trisomies 21 and 13 were ≤ 0.0001%. In the two cases of trisomy 13, the probability score for trisomy 13 was > 59% and the scores for trisomies 21 and 18 were ≤ 0.0001%. In the 200 euploid pregnancies with a test result, the probability score was < 0.08% for trisomy 21, < 0.001% for trisomy 18 and < 0.002% for trisomy 13. Therefore, the IONA test detected 100% of all three trisomies, with a false-positive rate of 0%.

Conclusion The IONA test successfully differentiated all cases of trisomies 21, 18 and 13 from euploid pregnancies. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

INTRODUCTION

Diagnosis of fetal aneuploidy relies on invasive testing by chorionic villus sampling (CVS) or amniocentesis in

pregnancies that are identified by screening to be at high risk for such aneuploidies¹. In many developed countries the most widely accepted method of screening at present is one that is based on a combination of maternal age, fetal nuchal translucency (NT) thickness, maternal serum free beta-human chorionic gonadotropin (β-hCG) and pregnancy-associated plasma protein-A (PAPP-A), that could identify approximately 90% of fetuses with trisomies 21, 18 or 13 at a false-positive rate (FPR) of 5%². A new method of screening for fetal trisomy relies on the examination of cell-free DNA (cfDNA) in maternal plasma³. Several studies in the last 4 years have reported the clinical validation and/or implementation of cfDNA testing and a recent meta-analysis of such studies weighted pooled detection rates (DR) and FPR in singleton pregnancies as 99.2% and 0.09%, respectively, for trisomy 21, 96.3% and 0.13% for trisomy 18, and 91.0% and 0.13% for trisomy 13⁴.

The IONA[®] test and IONA software (Premaita Health plc, Manchester, UK) is a cfDNA test developed recently which uses the Ion Proton™ sequencing platform (Thermo Fisher Scientific, Waltham, MA, USA) and an algorithm that determines the relative number of chromosomal copies, enabling the detection of fetal trisomies⁵. The objective of this study was to assess the potential performance of the IONA test and IONA software in screening for trisomies 21, 18 and 13 at 11–13 weeks' gestation.

METHODS

This was a nested case–control study of stored maternal plasma from 242 singleton pregnancies at 11–13 weeks' gestation, including 201 with euploid fetuses, 35 with trisomy 21, four with trisomy 18 and two with trisomy 13. In all cases fetal karyotyping was performed following CVS in our tertiary referral center because screening by the combined test had demonstrated an increased risk for trisomies 21, 18 or 13. Gestational age was

Correspondence to: Dr L. C. Poon, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, Denmark Hill, London, SE5 9RS, UK (e-mail: chiu_yee_liona.poon@kcl.ac.uk)

Accepted: 13 September 2015

determined from the measurement of fetal crown–rump length (CRL)⁶.

Maternal venous blood (10 mL) was collected before CVS in ethylenediaminetetraacetic acid vacutainer tubes (Becton Dickinson UK Limited, Oxfordshire, UK) and was processed within 15 min of collection. Samples were centrifuged at 2000 g for 10 min to separate the plasma from packed cells and buffy coat (plasma 1) and again at 16 000 g for 10 min to further separate cell debris (plasma 2). Plasma 1 and 2 (2 mL each) were divided into 0.5-mL aliquots in separate Eppendorf tubes that were labeled with a unique patient identifier and stored at -80°C until subsequent analysis. Written informed consent was obtained from the women who agreed to participate in the study, which was approved by the King's College Hospital Ethics Committee.

We searched our database and selected 35 consecutive cases of trisomy 21, four cases of trisomy 18 and two cases of trisomy 13 that had 2 mL of stored plasma 2 available. Two hundred and one euploid control subjects were selected; none of their samples was previously thawed and refrozen. Maternal blood was collected between April 2007 and June 2012.

Laboratory analysis

Plasma samples (four tubes of 0.5 mL per patient) from selected cases were sent from London to the laboratory of Premaita Health plc in Manchester, UK. The following information was provided to Premaita for each case: patient-unique identifier, maternal age, weight and height, racial origin, method of conception, smoking habit, gestational age in weeks, fetal CRL, and date of blood collection. Before evaluation for fetal trisomy, Premaita assessed each sample for volume, adequacy of labeling,

and risk of contamination or sample mixing and informed us that all samples met their acceptance criteria. The 242 samples were then analyzed using the IONA[®] test⁵. Results were provided for the risk of trisomies 21, 18 and 13 in each case and the correlation between the assay results and the fetal karyotype was determined.

Statistical analysis

Descriptive statistics are presented as median (interquartile range (IQR)) for continuous variables and *n* (%) for categorical variables. Probability scores for each trisomy are presented in scatterplots. DR and FPR are reported based on a predefined cut-off for probability. An age-adjusted probability of trisomy calculated to be ≥ 1 in 150 was considered a positive result, as used in the UK National Health Service (NHS)⁷. Point estimates with 95% CI have been provided.

RESULTS

All 242 samples were processed with the IONA test, however, one of these did not meet the validity criteria applied by the IONA software owing to a low fetal fraction and was excluded from subsequent analysis. In this case, sampling was performed at 13 weeks' gestation, the maternal weight was 86 kg and the serum PAPP-A multiples of the median (MoM) value was 1.316 and there were no obvious reasons for why the fetal fraction was low. Results were generated by the IONA software for the remaining 241 samples.

The characteristics of the euploid and aneuploid pregnancies are summarized in Table 1. In all 35 cases of trisomy 21, the probability score for trisomy 21

Table 1 Characteristics of study population of women with a singleton pregnancy who underwent cell-free DNA analysis using the IONA[®] test, grouped according to karyotype obtained following chorionic villus sampling

Characteristic	Euploid (n = 200)	Trisomy 21 (n = 35)	Trisomy 18 (n = 4)	Trisomy 13 (n = 2)
Maternal age (years)	32.9 (29.2–36.9)	38.0 (35.5–40.5)	37.7 (30.0–40.1)	32.1 (31.3–32.1)
Maternal weight (kg)	67.0 (60.0–76.0)	63.6 (57.2–74.5)	68.5 (60.9–72.0)	53.6 (50.8–53.6)
Maternal height (cm)	165 (160–170)	165 (160–167)	172 (166–173)	163 (162–163)
GA at testing (weeks)	12.7 (12.2–13.1)	13.0 (12.4–13.6)	11.9 (11.4–13.3)	12.8 (12.0–12.8)
Racial origin				
Caucasian	146 (73.0)	31 (88.6)	2 (50.0)	2 (100.0)
Afro-Caribbean	38 (19.0)	1 (2.9)	1 (25.0)	0 (0)
South Asian	5 (2.5)	3 (8.6)	0 (0)	0 (0)
East Asian	3 (1.5)	0 (0)	0 (0)	0 (0)
Mixed	8 (4.0)	0 (0)	1 (25.0)	0 (0)
Cigarette smoker	10 (5.0)	3 (8.6)	1 (25.0)	0 (0)
Mode of conception				
Spontaneous	189 (94.5)	33 (94.3)	2 (50.0)	2 (100.0)
Ovulation drugs	2 (1.0)	2 (5.7)	0 (0)	0 (0)
In-vitro fertilization	9 (4.5)	0 (0)	2 (50.0)	0 (0)
Fetal NT (mm)	1.8 (1.5–2.2)	4.2 (3.1–5.3)	2.5 (1.6–6.8)	5.9 (2.8–5.9)
Free β -hCG MoM	1.232 (0.821–1.950)	2.551 (1.696–3.615)	0.352 (0.224–0.901)	1.136 (0.515–1.136)
PAPP-A MoM	1.144 (0.736–1.612)	0.708 (0.500–1.157)	0.232 (0.145–0.288)	0.621 (0.146–0.621)

Data are given as median (interquartile range) or *n* (%). β -hCG, beta-human chorionic gonadotropin; GA, gestational age; MoM, multiples of the median; NT, nuchal translucency; PAPP-A, pregnancy-associated plasma protein-A.




Figure 1 Probability scores for trisomy 21 (a), trisomy 18 (b) and trisomy 13 (c) in singleton pregnancies with trisomic (●) or euploid (○) fetuses that underwent cell-free DNA analysis using the IONA[®] test.

was > 95% and the scores for trisomies 18 and 13 were $\leq 0.0001\%$ (Figure 1). In all four cases of trisomy 18, the probability score for trisomy 18 was > 77% and the scores for trisomies 21 and 13 were $\leq 0.0001\%$. In the two cases of trisomy 13, the probability score for trisomy 13 was > 59% and the scores for trisomies 21 and 18 were $\leq 0.0001\%$. In the 200 euploid pregnancies with a test result, the probability score was < 0.08% for trisomy 21, < 0.001% for trisomy 18 and < 0.002% for trisomy 13. Therefore, the DR for trisomy 21 was 100% (95% CI, 90.1–100.0%; 35/35 cases), the DR for trisomy 18 was 100% (95% CI, 51.0–100.0%; 4/4 cases) and the DR for trisomy 13 was 100% (95% CI, 34.2–100.0%; 2/2 cases), with a FPR of 0% (95% CI, 0.0–1.9%; 200/200 cases).

DISCUSSION

Main findings of the study

This nested case–control study has demonstrated that, in pregnancies considered by the combined test to be at high risk for trisomies 21, 18 or 13, cfDNA testing of maternal plasma at 11–13 weeks' gestation using the IONA test identified correctly all trisomic pregnancies, at a FPR of 0%.

Comparison with findings from previous studies

The performance of the IONA test in the detection of trisomy 21 is comparable to the reported performance of cfDNA analysis in a recent meta-analysis⁴. Although the number of cases of trisomies 18 and 13 is too small for definitive conclusions to be drawn, the performance of the test may be higher than in other studies^{8–30}. In this study, compared with most previous publications on cfDNA testing, we used samples that were obtained at 11–13 weeks exclusively. This is important because, in the last decade, there has been a major shift from second- to first-trimester screening and diagnosis of aneuploidies.

Strengths and limitations of the study

The study has several strengths, including a large number of pregnancies affected by trisomy 21, laboratory staff blinded to the fetal karyotype or outcome at the time of cfDNA testing, and complete outcome data. The study examined the application of a novel technique and software. The main limitations include its retrospective design, inclusion of only high-risk pregnancies and a small number of pregnancies affected by trisomies 18 or 13. However, the reported performance of cfDNA testing is similar in studies in both high- and low-risk populations^{11,22,23,25,29,31–34}, we therefore believe that the results of the study can be applied to a general population but in an ideal situation such results should be validated in a prospective study.

Conclusion

In this study, the IONA test differentiated all cases of trisomy 21, 18 and 13 from euploid pregnancies.

ACKNOWLEDGMENTS

This study was supported by a grant from The Fetal Medicine Foundation (UK Charity No: 1037116). The IONA[®] test was provided by Premaitha Health plc, Manchester, UK.

REFERENCES

- Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. *Prenat Diagn* 2011; 31: 7–15.
- Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. *Fetal Diagn Ther* 2014; 35: 118–126.
- Lo YMD, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. *Lancet* 1997; 350: 485–487.
- Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. *Ultrasound Obstet Gynecol* 2015; 45: 249–266.
- Papageorghiou AT, Khalil A, Forman M, Hulme R, Mazey R, Mousa HA, Johnstone ED, McKelvey A, Cohen KE, Rislely M, Denman W, Kelly B. Clinical evaluation of the IONA test: a non-invasive prenatal screening test for trisomies 21, 18 and 13. *Ultrasound Obstet Gynecol* 2016; 47: 188–193.

6. Robinson HP, Fleming JE. A critical evaluation of sonar crown rump length measurements. *Br J Obstet Gynaecol* 1975; **82**: 702–710.
7. Patient. Prenatal screening and diagnosis of Down's syndrome. <http://patient.info/health/prenatal-screening-and-diagnosis-of-downs-syndrome>.
8. Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KC, Leung TY, Jiang P, Zheng YW, Lun FM, Chan LY, Jin Y, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. *PLoS One* 2011; **6**: e21791.
9. Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, Rava RP. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. *Clin Chem* 2011; **57**: 1042–1049.
10. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 2012; **206**: 322.e1–5.
11. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. *Am J Obstet Gynecol* 2012; **207**: 374.e1–6.
12. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J 3rd, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson MW, Oepkes D, Holleman D, Sparks AB, Oliphant A, Song K. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 2012; **207**: 137.e1–8.
13. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. *Am J Obstet Gynecol* 2012; **206**: 319.e1–9.
14. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol* 2012; **119**: 890–901.
15. Jiang F, Ren J, Chen F, Zhou Y, Xie J, Dan S, Su Y, Xie J, Yin B, Su W, Zhang H, Wang W, Chai X, Lin L, Guo H, Li Q, Li P, Yuan Y, Pan X, Li Y, Liu L, Chen H, Xuan Z, Chen S, Zhang C, Zhang H, Tian Z, Zhang Z, Jiang H, Zhao L, Zheng W, Li S, Li Y, Wang J, Wang J, Zhang X. Noninvasive Fetal Trisomy (NIFTY) test: an advanced noninvasive prenatal diagnosis methodology for fetal autosomal and sex chromosomal aneuploidies. *BMC Med Genomics* 2012; **5**: 57.
16. Lau TK, Chen F, Pan X, Pooh RK, Jiang F, Li Y, Jiang H, Li X, Chen S, Zhang X. Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing. *J Matern Fetal Neonatal Med* 2012; **25**: 1370–1374.
17. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrlich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. *Genet Med* 2012; **14**: 296–305.
18. Ashoor G, Syngelaki A, Wang E, Struble C, Oliphant A, Song K, Nicolaides KH. Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis. *Ultrasound Obstet Gynecol* 2013; **41**: 21–25.
19. Guex N, Iseli C, Syngelaki A, Pescia G, Nicolaides KH, Xenarios I, Conrad B. A robust second-generation genome-wide test for fetal aneuploidy based on shotgun sequencing cell-free DNA in maternal blood. *Prenat Diagn* 2013; **33**: 707–710.
20. Liang D, Lv W, Wang H, Xu L, Liu J, Li H, Hu L, Peng Y, Wu L. Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing. *Prenat Diagn* 2013; **33**: 409–415.
21. Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation study of maternal blood cell-free DNA testing by targeted sequencing of single-nucleotide polymorphisms at chromosomes 13, 18, 21, X, and Y. *Prenat Diagn* 2013; **33**: 575–579.
22. Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. *Prenat Diagn* 2013; **33**: 700–706.
23. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, Craig JA, Chudova DI, Devers PL, Jones KW, Oliver K, Rava RP, Sehnert AJ; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. *N Engl J Med* 2014; **370**: 799–808.
24. Hall MP, Hill M, Zimmermann B, Sigurjonsson S, Westemeyer M, Saucier J, Demko Z, Rabinowitz M. Non-invasive prenatal detection of trisomy 13 using a single nucleotide polymorphism- and informatics-based approach. *PLoS One* 2014; **9**: e96677.
25. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, Hall MP, Dodd M, Lacroute P, Stosic M, Chopra N, Hunkapiller N, Prosen DE, McAdoo S, Demko Z, Siddiqui A, Hill M, Rabinowitz M. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. *Obstet Gynecol* 2014; **124**: 210–218.
26. Porreco RP, Garite TJ, Maurel K, Marusiak B; Obstetrix Collaborative Research Network, Ehrich M, vanden Boom D, Deciu C, Bombard A. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. *Am J Obstet Gynecol* 2014; **211**: 365.e1–12.
27. Shaw SW, Hsiao CH, Chen CY, Ren Y, Tian F, Tsai C, Chen M, Cheng PJ. Noninvasive prenatal testing for whole fetal chromosomal aneuploidies: a multicenter prospective cohort trial in Taiwan. *Fetal Diagn Ther* 2014; **35**: 13–17.
28. Stumm M, Entezami M, Haug K, Blank C, Wu stemann M, Schulze B, Raabe-Meyer G, Hempel M, Schelling M, Ostermayer E, Langer-Freitag S, Burkhardt T, Zimmermann R, Schleicher T, Weil B, Schock U, Smerdka P, Gromminger S, Kumar Y, Hofmann W. Diagnostic accuracy of random massively parallel sequencing for non-invasive prenatal detection of common autosomal aneuploidies: a collaborative study in Europe. *Prenat Diagn* 2014; **34**: 185–191.
29. Quezada MS, Gil MM, Francisco C, Orosz G, Nicolaides KH. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeks. *Ultrasound Obstet Gynecol* 2015; **45**: 36–41.
30. Song Y, Huang S, Zhou X, Jiang Y, Qi Q, Bian X, Zhang J, Yan Y, Cram DS, Liu J. Non-invasive prenatal testing for fetal aneuploidies in the first trimester of pregnancy. *Ultrasound Obstet Gynecol* 2015; **45**: 55–60.
31. Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH. Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. *Ultrasound Obstet Gynecol* 2013; **42**: 34–40.
32. Comas C, Echevarria M, Rodriguez MA, Prats P, Rodriguez I, Serra B. Initial experience with non-invasive prenatal testing of cell-free DNA for major chromosomal anomalies in a clinical setting. *J Matern Fetal Neonatal Med* 2014; **12**: 1–6.
33. Zhang H, Gao Y, Jiang F, Meili F, Yuan Y, Guo Y, Zhu Z, Lin M, Liu Q, Tian Z, Zhang H, Chen F, Lau KL, Zhao L, Yi X, Yin Y, Wang W. Non-invasive prenatal testing for trisomies 21, 18 and 13 – Clinical experience from 146,958 pregnancies. *Ultrasound Obstet Gynecol* 2015; **45**: 530–538.
34. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, Tomlinson MW, Pereira L, Spitz JL, Holleman D, Cuckle H, Musci TJ, Wapner RJ. Cell-free DNA analysis for noninvasive examination of trisomy. *N Engl J Med* 2015; **372**: 1589–1597.